Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2012

01-03-2012 | Review Article

Antifungal Chemoprophylaxis in Children and Adolescents with Haematological Malignancies and Following Allogeneic Haematopoietic Stem Cell Transplantation

Review of the Literature and Options for Clinical Practice

Authors: Athanasios Tragiannidis, Charalampos Dokos, Thomas Lehrnbecher, Professor Andreas H. Groll, MD

Published in: Drugs | Issue 5/2012

Login to get access

Abstract

Invasive opportunistic fungal infections are important causes of morbidity and mortality in children and adolescents with cancer or haematopoietic stem cell transplantation (HSCT). Difficulties in establishing the diagnosis continue to delay antifungal therapy, and this has been shown to adversely impact on survival. Apart from ongoing attempts to improve early recognition, effective chemoprophylaxis of invasive fungal infections remains a goal of high priority in populations with disease-related incidence rates of 10% or higher. These include patients with acute myeloid leukaemia, high-risk acute lymphoblastic leukaemias, recurrent leukaemias and those following allogeneic HSCT. Incidence rates in other paediatric cancer entities, including autologous HSCT, are considerably lower and do not justify the general implementation of antifungal prophylaxis.
The difficulties in obtaining a timely diagnosis, the consequences of infectious morbidity on delaying anticancer treatment, and mortality rates >20% and >50% for invasive yeast and mould infections, respectively, provide a clear rationale for antifungal prophylaxis in high-risk populations. However, while antifungal prophylaxis has become part of infectious disease supportive care algorithms in most paediatric leukaemia and allogeneic transplantation programmes, antifungal prophylaxis remains a topic of controversy, with no clear consensus amongst different centres and groups. This is largely based on the limited paediatric data, with only a small number of meaningful studies, and on the fact that the scientific evidence for the benefit of antifungal prophylaxis has been generated exclusively by prospective, randomized, clinical phase III trials conducted in adults with comparable, but not similar conditions.
In this article, we briefly review the epidemiology of invasive fungal infections in children and adolescents with cancer and following HSCT; delineate regulatory principles of paediatric drug development with relevant examples for their successful implementation with new antifungal compounds; provide information on the pharmacology and paediatric development of current antifungal compounds; discuss for each compound the evidence for effectiveness as primary or secondary antifungal prophylaxis in adults and the pertinent data published in paediatric patients; and conclude by providing practical options for prophylaxis in children and adolescents with haematological malignancies and following allogeneic HSCT.
Literature
1.
Benjamin Jr DK, Miller WC, Bayliff S, et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: 227–34PubMed
2.
Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004 Jul; 23(7): 635–41PubMed
3.
Zaoutis T, Coffin S, Chu J, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J 2005; 24: 736–9PubMed
4.
Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immuno-compromised children in the United States, 2000. Pediatrics 2006; 117: 711–6
5.
Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27: 135–40PubMed
6.
Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: e1286–94PubMed
7.
Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J Pediatr Hematol Oncol 2009 Dec; 31(12): 911–9PubMed
8.
Hale KA, Shaw PJ, Dalla-Pozza L, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 2010 Apr; 149(2): 263–72PubMed
9.
Mor M, Gilad G, Kornreich L, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56: 1092–7PubMed
10.
Dornbusch HJ, Groll A, Walsh TJ. Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect 2010; 16: 1328–34PubMed
11.
Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis: disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993 Aug–Sep; 17(2): 103–9PubMed
12.
Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46: 212–29PubMed
13.
Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices and new data. Pediatr Blood Cancer. Epub 2011 Nov 18
14.
Gramatges MM, Winter SS. Recommendations for broader coverage antifungal prophylaxis in childhood acute myeloid leukemia: ASH evidence-based review 2011. Hematology Am Soc Hematol Educ Program 2011: 2011: 374–6PubMed
15.
Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999–1004PubMed
16.
Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–66PubMed
17.
Kobayashi R, Kaneda M, Sato T, et al. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol 2008; 30: 886–90PubMed
18.
Kaya Z, Gursel T, Kocak U, et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009; 52: 470–5PubMed
19.
Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer 2010; 55: 1103–7PubMed
20.
Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634–43PubMed
21.
Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695–703PubMed
22.
Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745–52PubMed
23.
Slavin MA, Sorrell TC, Marriott D, et al.; Australian Candidemia Study, Australasian Society for Infectious Diseases. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010 May; 65(5): 1042–51PubMed
24.
Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 Aug 1; 39(3): 309–17PubMed
25.
Geffers C, Gastmeier P. Nosocomial infections and multi-drug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System). Dtsch Arztebl Int 2011 Feb; 108(6): 87–93PubMedCentralPubMed
26.
Tragiannidis A, Fegeler W, Rellensmann G, et al. Candidaemia in a European Paediatric University Hospital: a 10-year observational study. Clin Microbiol Infect 2012 Feb; 18(2): e27–30PubMed
27.
Mullen CA, Abd El-Baki H, Samir H, et al. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer 2003; 11: 321–5PubMed
28.
Roilides E, Kadiltsoglou I, Zahides D, et al. Invasive can-didosis in pediatric patients. Clin Microbiol Infect 1997 Apr; 3(2): 192–7PubMed
29.
Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003 Aug; 22(8): 686–91PubMed
30.
Pasqualotto AC, de Moraes AB, Zanini RR, et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 2007; 28: 799–804PubMed
31.
Blyth CC, Chen SC, Slavin MA, et al., Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123: 1360–8PubMed
32.
Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010 Sep 1; 51(5): e38–45PubMedCentralPubMed
33.
Dutta A, Palazzi DL. Candida non-albicans versus candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011 Aug; 30(8): 664–8PubMed
34.
Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin Microbiol Infect 2010 Sep; 16(9): 1321–7PubMed
35.
Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–66PubMed
36.
McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–7PubMed
37.
Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre: epidemiology, management and long-term survival. Mycoses 1999; 42: 431–42PubMed
38.
Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425–9PubMed
39.
Pongas GN, Lewis RE, Samonis G, et al. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15 Suppl. 5: 93–7PubMed
40.
Saegeman V, Maertens J, Meersseman W, et al. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010; 16: 1456–8PubMedCentralPubMed
41.
Groll AH. Drug therapy in paediatric patients. Lancet 2001; 357(9257): 719PubMed
42.
43.
44.
Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Federal Register 1998; 63: 66632–72
45.
Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536–45PubMedCentralPubMed
46.
Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877–84PubMed
47.
Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29: 415–20PubMed
48.
Li C, Sun P, Dong Y, et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother 2011 May; 55(5): 2098–105PubMedCentralPubMed
49.
Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009; 28: 1132–5PubMed
50.
Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317–24PubMedCentralPubMed
51.
Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27: 820–6PubMed
52.
van Burik JA, Ratanatharathorn V, Stepan DE, et al., National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–16PubMed
53.
Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714–9PubMedCentralPubMed
54.
Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011 Jun; 30(6): e97–102PubMed
55.
Mora-Duarte J, Betts R, Rotstein C, et al., Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–9PubMed
56.
Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–402PubMed
57.
Kuse ER, Chetchotisakd P, da Cunha CA, et al., Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369(9572): 1519–27PubMed
58.
Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166–72PubMedCentralPubMed
59.
Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935–44PubMedCentralPubMed
60.
Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocom-promised children. Antimicrob Agents Chemother 2010 Oct; 54(10): 4116–23PubMedCentralPubMed
61.
Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011 Dec; 55(12): 5770–9. Epub 2011 Oct 3PubMedCentralPubMed
62.
Driscoll TA, Frangoul H, Nemecek ER, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother 2011 Dec; 55(12): 5780–9PubMedCentralPubMed
63.
Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16: 1343–53PubMed
64.
Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherary recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230–46PubMed
65.
Cornely OA, Ullmann AJ, Karthaous M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365–72PubMed
66.
Glasmacher A, Prentice AG, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 21: 4616–26
67.
Kim YJ, Sung KW, Hwang HS, et al. Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. Yonsei Med J 2011; 52: 293–300PubMedCentralPubMed
68.
Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003 Mar; 17(1): 159–91PubMed
69.
Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 1096–102PubMed
70.
Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 2008; 14 Suppl. 4: 55–64PubMed
71.
Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306–12PubMed
72.
Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163–8PubMed
73.
Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003; 97(2): 450–6PubMed
74.
Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401–8PubMed
75.
Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006; 50: 935–42PubMedCentralPubMed
76.
Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711–8PubMed
77.
Ringdén O, Andström EE, Remberger M, et al. Prophylaxis and therapy using liposomal amphotericin B (Am-Bisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplant 1997; 1: 124–9PubMed
78.
Uhlenbrock S, Zimmermann M, Fegeler W, et al. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study. Mycoses 2001; 44: 455–63PubMed
79.
Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in pediatric hematologic malignancy patients. Clin Microbiol Infect 2011 Dec; 17(12): 1868–74PubMed
80.
Mehta P, Vinks A, Filipovich A, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006; 12: 235–40PubMed
81.
Kolve H, Ahlke E, Fegeler W, et al. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother 2009; 64: 383–7PubMed
82.
Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120: 987–93PubMed
83.
Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994; 13: 325–9PubMed
84.
Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43: 1955–60PubMedCentralPubMed
85.
de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42: 404–8PubMedCentralPubMed
86.
Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46: 2554–63PubMedCentralPubMed
87.
Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45: 1099–114PubMed
88.
Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999; 24: 1089–93PubMed
89.
Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother 2007; 51: 2668–73PubMedCentralPubMed
90.
Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–51PubMed
91.
Slavin M, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545–52PubMed
92.
Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055–61PubMed
93.
Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994; 120: 913–8
94.
Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331–40
95.
Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705–13PubMed
96.
Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–33PubMed
97.
Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin Infect Dis 1999; 28: 250–5
98.
Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131: 22–8PubMed
99.
Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multi-centre Study Group. Eur J Clin Microbiol Infect Dis 1994; 13: 330–7
100.
Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer 2007; 15: 213–20PubMed
101.
Grigull L, Kuehlke O, Beilken A, et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 2007; 11: 261–6PubMed
102.
Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–11PubMed
103.
Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782–8PubMedCentralPubMed
104.
Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224–9PubMedCentralPubMed
105.
Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010;88: 115–9PubMed
106.
Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007; 51: 812–8PubMedCentralPubMed
107.
Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240–8PubMed
108.
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348–59PubMed
109.
Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–47PubMed
110.
Wingard JR, Carter SL, Walsh TJ, et al., Blood and Marrow Transplant Clinical, Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–8PubMedCentralPubMed
111.
Marks DI, Pagliuca A, Kibbler CC, et al., IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155: 318–27PubMedCentralPubMed
112.
Mandhaniya S, Swaroop C, Thulkar S, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. Pediatr Hematol Oncol 2011; 33: e333–41
113.
Molina JR, Serrano J, Sánchez-García J, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marrow Transplant. Epub 2011 May 16
114.
Panagopoulou P, Fragandrea-Sidi F, Roilides E, et al. Antifungal prophylaxis with voriconazole in paediatric patients treated for hematological malignancies. Haematologica 2010; 95 Suppl. 2: 363
115.
Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27: 1644–50PubMed
116.
Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006; 50: 143–7PubMedCentralPubMed
117.
Kusuki S, Hashii Y, Yoshida H, et al. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer 2009; 53: 605–9PubMed
118.
Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16: 1458–62PubMed
119.
Walsh TJ, Whitcomb PO, Revankar SG, et al. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995 Dec 1; 76(11): 2357–62PubMed
120.
Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998 May; 26(5): 1098–103PubMed
121.
Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928–36PubMedCentralPubMed
122.
Allinson K, Kolve H, Gumbinger HG, et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cellrecipients. J Antimicrob Chemother 2008; 61: 734–42PubMed
123.
Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943–8PubMed
124.
Cordonnier C, Rovira M, Maertens J, et al., Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VO-SIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762–8PubMedCentralPubMed
125.
Krüger WH, Rüssmann B, de Wit M, et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005; 113: 104–8PubMed
126.
Vehreschild JJ, Sieniawski M, Reuter S, et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents 2009; 34: 446–50PubMed
127.
de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40: 245–9PubMed
128.
Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42(7–8): 443–51PubMed
129.
Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multi-centre survey. Eur J Clin Microbiol Infect Dis 2010 Aug; 29(8): 1043–5PubMed
130.
Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008 May; 14 Suppl. 4: 5–24PubMed
Metadata
Title
Antifungal Chemoprophylaxis in Children and Adolescents with Haematological Malignancies and Following Allogeneic Haematopoietic Stem Cell Transplantation
Review of the Literature and Options for Clinical Practice
Authors
Athanasios Tragiannidis
Charalampos Dokos
Thomas Lehrnbecher
Professor Andreas H. Groll, MD
Publication date
01-03-2012
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2012
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11599810-000000000-00000

Other articles of this Issue 5/2012

Drugs 5/2012 Go to the issue

Adis Drug Evaluation

Tranexamic Acid

Adis Drug Evaluation

Rasagiline

Systematic Review

The Cost Effectiveness of Human Papillomavirus Vaccines

Current Opinion

Induction Therapy in Renal Transplant Recipients

Review Article

Medical Therapy of Endometrial Cancer

Adis Drug Evaluation

Telaprevir